Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.

@article{Ng2012PhaseIT,
  title={Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.},
  author={Q-S Ng and Henry C. Mandeville and Vivien Goh and Roberto Alonzi and Jessica S Milner and Dawn Carnell and Khalda Meer and Anwar R. Padhani and Michele I Saunders and Peter J. Hoskin},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 1},
  pages={231-7}
}
BACKGROUND The vascular disrupting agent combretastatin-A4-phosphate (CA4P) demonstrated antitumour activity in preclinical studies when combined with radiation. METHODS Patients with non-small-cell lung cancer (NSCLC), prostate adenocarcinoma, and squamous cell carcinoma of the head and neck (SCCHN) received 27 Gy in 6 fractions treating twice weekly over 3 weeks, 55 Gy in 20 fractions over 4 weeks, and 66 Gy in 33 fractions over 6 weeks respectively. CA4P was escalated from 50 mg/m2 to 63… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…